Literature DB >> 29662543

Optical improvements in the diagnosis of bladder cancer: implications for clinical practice.

Tina Schubert1, Steffen Rausch1, Omar Fahmy2, Georgios Gakis1, Arnulf Stenzl3.   

Abstract

BACKGROUND: For over 100 years white-light cystoscopy has remained the gold-standard technique for the detection of bladder cancer (BCa). Some limitations in the detection of flat lesions (CIS), the differentiation between inflammation and malignancy, the inaccurate determination of the tumor margin status as well as the tumor depth, have led to a variety of technological improvements. The aim of this review is to evaluate the impact of these improvements in the diagnosis of BCa and their effectiveness in clinical practice.
METHODS: A systematic literature search was conducted according to the PRISMA statement to identify studies reporting on imaging modalities in the diagnosis of NMIBC between 2000 and 2017. A two-stage selection process was utilized to determine eligible studies. A total of 74 studies were considered for final analysis.
RESULTS: Optical imaging technologies have emerged as an adjunct to white-light cystoscopy and can be classified according to their scope as macroscopic, microscopic and molecular. Macroscopic techniques including photodynamic diagnosis (PDD), narrow-band imaging (NBI) and the Storz Professional Image Enhancement System (IMAGE1 S, formerly known as SPIES) are similar to white-light cystoscopy, but are superior in the detection of bladder tumors by means of contrast enhancement. Especially the detection rate of very mute lesions in the bladder mucosa (CIS) could be significantly increased by the use of these methods. Microscopic imaging techniques like confocal laser endomicroscopy and optical coherence tomography permit a real-time high-resolution assessment of the bladder mucosa at a cellular and sub-cellular level with spatial resolutions similar to histology, enabling the surgeon to perform an 'optical biopsy'. Molecular techniques are based on the combination of optical imaging technologies with fluorescence labeling of cancer-specific molecular agents like antibodies. This labeling is intended to favor an optical distinction between benign and malignant tissue.
CONCLUSIONS: Optical improvements of the standard white-light cystoscopy have proven their benefit in the detection of BCa and have found their way into clinical practice. Especially the combination of macroscopic and microscopic techniques may improve diagnostic accuracy. Nevertheless, HAL-PDD guided cystoscopy is the only approach approved for routine use in the diagnosis of BCa by most urological associations in the EU and USA to date.

Entities:  

Keywords:  bladder cancer; cystoscopy; diagnosis; image; optical

Year:  2017        PMID: 29662543      PMCID: PMC5896854          DOI: 10.1177/1756287217720401

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  61 in total

Review 1.  Global randomized narrow band imaging versus white light study in nonmuscle invasive bladder cancer: accession to the first milestone-enrollment of 600 patients.

Authors:  Seiji Naito; Sonja van Rees Vellinga; Jean de la Rosette
Journal:  J Endourol       Date:  2013-01       Impact factor: 2.942

2.  Multiphoton microscopy for structure identification in human prostate and periprostatic tissue: implications in prostate cancer surgery.

Authors:  Ashutosh K Tewari; Maria M Shevchuk; Joshua Sterling; Sonal Grover; Michael Herman; Rajiv Yadav; Kumaran Mudalair; Abhishek Srivastava; Mark A Rubin; Warren R Zipfel; Frederick R Maxfield; Chris Xu; Watt W Webb; Sushmita Mukherjee
Journal:  BJU Int       Date:  2011-03-28       Impact factor: 5.588

3.  Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial.

Authors:  Arnulf Stenzl; Hannes Penkoff; Elfriede Dajc-Sommerer; Andreas Zumbraegel; Lorenz Hoeltl; Michael Scholz; Claus Riedl; Josef Bugelnig; Alfred Hobisch; Maximilian Burger; Gregor Mikuz; Uwe Pichlmeier
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

4.  Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?

Authors:  Bogdan Geavlete; Razvan Multescu; Dragos Georgescu; Marian Jecu; Florin Stanescu; Petrisor Geavlete
Journal:  BJU Int       Date:  2011-06-28       Impact factor: 5.588

Review 5.  Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.

Authors:  Michael Rink; Marko Babjuk; James W F Catto; Patrice Jichlinski; Shahrokh F Shariat; Arnulf Stenzl; Herbert Stepp; Dirk Zaak; J Alfred Witjes
Journal:  Eur Urol       Date:  2013-07-19       Impact factor: 20.096

6.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Authors:  Arnulf Stenzl; Maximilian Burger; Yves Fradet; Lance A Mynderse; Mark S Soloway; J Alfred Witjes; Martin Kriegmair; Alexander Karl; Yu Shen; H Barton Grossman
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

7.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

Authors:  Yves Fradet; H Barton Grossman; Leonard Gomella; Seth Lerner; Michael Cookson; David Albala; Michael J Droller
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

8.  Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study.

Authors:  Christof Schäfauer; Dominique Ettori; Morgan Rouprêt; Véronique Phé; Jean-Michel Tualle; Eric Tinet; Sigrid Avrillier; Christophe Egrot; Olivier Traxer; Olivier Cussenot
Journal:  J Urol       Date:  2013-02-04       Impact factor: 7.450

Review 9.  Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis.

Authors:  Weiting Kang; Zilian Cui; Qianqian Chen; Dong Zhang; Haiyang Zhang; Xunbo Jin
Journal:  Oncotarget       Date:  2017-04-04

10.  Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study.

Authors:  Marcus Horstmann; Severine Banek; Georgios Gakis; Tilman Todenhöfer; Stefan Aufderklamm; Joerg Hennenlotter; Arnulf Stenzl; Christian Schwentner
Journal:  Springerplus       Date:  2014-01-13
View more
  9 in total

1.  Experience of a tertiary referral center in managing bladder cancer in conjunction with neurogenic bladder.

Authors:  Gianluca Sampogna; Matteo Maltagliati; Antonio Galfano; Aldo Bocciardi; Bernardo Rocco; Salvatore Micali; Emanuele Montanari; Michele Spinelli
Journal:  Spinal Cord Ser Cases       Date:  2020-07-09

Review 2.  [Enhanced imaging in urological endoscopy].

Authors:  M C Kriegmair; S Hein; D S Schoeb; H Zappe; R Suárez-Ibarrola; F Waldbillig; B Gruene; P-F Pohlmann; F Praus; K Wilhelm; C Gratzke; A Miernik; C Bolenz
Journal:  Urologe A       Date:  2020-12-10       Impact factor: 0.639

3.  Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-08-12

4.  Label-free optical redox ratio from urinary extracellular vesicles as a screening biomarker for bladder cancer.

Authors:  Jaena Park; Rebecca L Kamerer; Marina Marjanovic; Janet E Sorrells; Sixian You; Ronit Barkalifa; Kimberly A Selting; Stephen A Boppart
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

5.  A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer.

Authors:  Julie Mariam Joshua; Meenu Vijayan; Ginil Kumar Pooleri
Journal:  Ther Adv Urol       Date:  2019-03-05

6.  lncRNA-UCA1 in the diagnosis of bladder cancer: A meta-analysis.

Authors:  Zhenshan Ding; Wenwei Ying; Yuhui He; Xing Chen; Yangtian Jiao; Jianfeng Wang; Xiaofeng Zhou
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

Review 7.  Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review.

Authors:  Prashant Motiram Mulawkar; Gyanendra Sharma; Ashwin Tamhankar; Utsav Shah; Rickaz Raheem
Journal:  Front Surg       Date:  2022-02-21

Review 8.  DNA Hydroxymethylation in Smoking-Associated Cancers.

Authors:  Ahmad Besaratinia; Amanda Caceres; Stella Tommasi
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

Review 9.  Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance.

Authors:  Nicholas Lee; Ashan Canagasingham; Mohit Bajaj; Ramesh Shanmugasundaram; Anthony Hutton; Joseph Bucci; Peter Graham; James Thompson; Jie Ni
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.